NHS to Roll Out Wegovy for Heart Patients After Approval Over a million people with cardiovascular disease eligible for weight-loss drug under new guidance

NHS to prescribe Wegovy for heart patients after watchdog approval

#NHS #HealthNews #HeartHealth #Wegovy #ObesityTreatment #NICE #MedicalNews #UKHealth #Cardiology

www.easterneye.biz/nhs-wegovy-h...

Mounjaro maker wants NHS drug price rises in return for more investment in UK US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers

#Mounjaro #NHSdrugpricerises #EliLilly #rebatescheme #Mounjaro #weightlossdrug #NHSdrugprices #NHSrebatescheme #antiobesitydrugs #NHScosteffectivenessthresholds #internationaldrugpricing #USUKdrugpricingdeal #brandedmedicines #obesity #obesitytreatment
zurl.co/6jNlv

Novo Nordisk expands weight-loss drug trials to overweight teenagers Novo Nordisk expands paediatric trials of appetite-suppressing GLP-1 drugs in teenagers, amid global shift to treating childhood obesity with prescription medication.

Novo Nordisk expands weight-loss drug trials to overweight teenagers

#ObesityTreatment #GLP1 #Pharma #HealthNews #AusNews

thedailyperspective.org/article/2026-03-16-novo-...

Oral GLP-1 Therapies in Obesity Treatment: Physician Survey US physician survey shows strong physician optimism for oral GLP-1 therapies and GLP-1 for obesity, reshaping obesity treatment and obesity management.

A survey of US physicians shows rising confidence in oral GLP-1 therapies as a major advancement in obesity treatment.

Read the study:
www.sperresearch.com/Case-Studies...

#GLP1ForObesity #ObesityTreatment

Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute

$NVO Ends Dispute, Partners with Hims & Hers to Sell GLP-1 Drugs, Boosting Obesity Medicine Access!
#healthtech #obesitytreatment #pharma

https://a777.lt/DMqx9g

Novo Nordisk’s new partnership with Bob Langer-founded Vivtex aims to turn injectable obesity drugs into pills.

vist.ly/4sv7a

#longevity #ObesityTreatment #NovoNordisk #DrugDelivery #OralBiologics #MetabolicHealth #BiotechPartnership #PharmaInnovation

Bariatric surgery isn’t “the easy way out.”

It’s the most effective long-term metabolic intervention we have.

The data on diabetes remission and mortality reduction isn’t even close.

Obesity is metabolic disease — not lack of willpower.

#BariatricSurgery #MetabolicHealth #ObesityTreatment

A once-a-month GLP-1/GIP drug candidate moves into US trials, signaling a new phase for metabolic medicine and longevity investing.

vist.ly/4skme

#longevity #WeightLoss #MetabolicHealth #ClinicalTrials #Pharma #ObesityTreatment #GLP1 #DrugDevelopment

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’ Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’ #Science #HealthandMedicine #PublicHealth #WeightLoss #Pharmaceuticals #ObesityTreatment

www.theguardian.com/business/2026/feb/23/weg...

Weight-loss pills are reshaping the market, but easier access brings new risks for patients and the industry.

vist.ly/4rwy8

#longevity #ObesityTreatment #MetabolicHealth #GLP1 #WeightLossDrugs #PatientSafety #PharmaTrends #HealthcareAccess

A large, new evidence review finds intermittent fasting may not help overweight or obese patients loose a significant amount of weight or improve their quality of life.

youtu.be/i_TxVWun2Ys

#IntermittentFasting #WeightLossResearch #DietTrends #ObesityTreatment #CalorieRestriction

Novo Nordisk expands Irish facility after Wegovy pill success Novo Nordisk CEO announces Irish facility expansion after Wegovy pill success, despite competition from Eli Lilly and legal action against Hims & Hers.

Novo Nordisk confirms Irish expansion to produce Wegovy® pills, meeting surging demand for obesity treatments. A key step in scaling global supply. #Pharma #Wegovy #Ireland #ObesityTreatment

Read below:
www.bioprocessintl.com/facilities-c...

Up to $287 million Series D1 backs CORXEL’s bid to bring a pill-based obesity and cardiometabolic treatment to a global stage.

longevity.technology/news/shangha...

#longevity #Biotech #GLP1 #MetabolicHealth #ObesityTreatment #Pharma #DrugDevelopment #ClinicalTrials #FundingNews

FDA designation fast-tracks a promising therapy for MASH, a silent liver disease tied to metabolic aging and long-term health.

longevity.technology/news/altimmu...

#longevity #FDABreakthrough #Altimmune #Pemvidutide #ObesityTreatment #MetabolicHealth #DrugDevelopment #HealthInnovation

Phase 1b trial of dual agonist results reveal strong weight loss, improved glucose control and promising liver benefits.

longevity.technology/news/metavia...

#longevity #ObesityTreatment #MetabolicHealth #Biotech #ClinicalTrials #Healthspan

Intragastric Balloon Market Size, Share, Trends, Report 2035 Intragastric Balloon Market to grow at 4.24% CAGR, reaching USD 3.51 Billion by 2035, driving, size, growth, global trends, competitive analysis and industry outlook 2025-2035.

Non-surgical weight loss solutions support growth in the Intragastric Balloon Market. www.marketresearchfuture.com/reports/intr...
#ObesityTreatment

The £279m trial starting in Greater Manchester that could affect thousands Up to 3,000 people will take part

#obesity #weightloss #weightlosstrial #GreaterManchester #weightlossjabs #weightlossmedication #realworldstudy #weightlossdrug #Mounjaro #GLP1drug #Tirzepatide #obesitytreatment #Zepbound #EliLilly #publichealth #cardiometabolicmedicine #weightrelatedhealthconditions
zurl.co/MmyhW

⚖️ Why Some Patients Lose Weight Faster Than Others

🔹 Weight loss speed differs from person to person due to factors like metabolism, hormonal balance, insulin resistance, body composition, and lifestyle habits.

#ObesityTreatment #HealthyWeightLoss #BariatricCare #HyderabadHealthcare

Eli Lilly's obesity pill shows promising results in maintaining long-term weight loss. Let's hope for a healthier future! #ObesityTreatment https://fefd.link/n5mh0

Phase III trial shows up to 28.7% weight loss, but tolerability remains a key concern for Eli Lilly’s triple-agonist therapy.

longevity.technology/news/lilly-w...

#longevity #Lilly #retatrutide #weightloss #healthinnovation #biotech #PhaseIII #obesitytreatment #GLP1 #healthgoals

🍽️ Palm Rule, Plate Rule & Timing Rule After Bariatric Surgery

🔹 After bariatric surgery, following simple methods like the palm rule and plate rule helps control portions while ensuring adequate nutrition.

ugalebariatrics.com/diet/

#PalmRule #PlateRule #MealTiming #ObesityTreatment

The World Health Organization (WHO) has just taken a historic step: for the first time, it has issued a global guideline on the use of GLP-1 medicines for treating obesity in adults (1 December 2025). If you’ve been hearing about “Wegovy”, “Ozempic”, “Mounjaro”, “Zepbound”, “fat jabs”, or just “the new weight-loss injections”, this guideline is basically the world’s top health body saying: Yes, …

wp.me/pgVjuO-57
#ObesityTreatment
#DiabetesResearch
#MetabolicHealth
#LifestyleMedicine
#WellnessCommunity
#HolisticHealing
#HealthyTransformation
#FitnessKnowledge
#BodyReform
#ClinicalHealth

A review of 48 clinical trials on GLP-1 safety suggests the popular meds probably have little to no effect on cancer risk.

youtu.be/tzKISp4ubqs

#GLP1 #Semaglutide #Tirzepatide #Dulaglutide #DiabetesCare #ObesityTreatment #CancerRisk #MedicalResearch #ClinicalTrials #HealthNews

WHO says weight loss drugs are ‘new chapter’ in fight against obesity WHO urges countries to make drugs such as Mounjaro more accessible to people and asks drugs companies to lower prices Weight loss drugs such as Mounjaro offer huge potential to tackle soaring obesity...

WHO says weight loss drugs are ‘new chapter’ in fight against obesity #Science #HealthandMedicine #Nutrition #ObesityTreatment #WeightLossDrugs #PublicHealth

How can movement be effectively integrated into #ObesityTreatment — particularly in light of new #GLP1 medications and other shifts in the #ObesityManagement landscape?

Explore the role of #PhysicalActivity in obesity treatment from our new publication: https://ow.ly/RkVQ50XxNk1

Accuracy of Large Language Model Responses Versus Internet Searches for Common Questions About Glucagon-Like Peptide-1 Receptor Agonist Therapy: Exploratory Simulation Study Background: Novel glucagon-like peptide 1 receptor agonists (GLP1RAs) for obesity treatment have generated much dialogue on digital media platforms. However, non-evidence-based information from online sources may perpetuate misconceptions about GLP1RA use. A promising new digital avenue for patient education is large language models (LLMs), which could potentially be used as an alternative to clarify questions about GLP1RA therapy. Objective: This study compared LLM (ChatGPT 4o) and internet (Google) search responses to simulated questions about GLP1RA therapy. Methods: Responses were graded by 2 independent evaluators based on Safety, Consensus with Guidelines, Objectivity, Reproducibility, Relevance and Explainability using a 5-point Likert Scale. Mean scores were compared using independent T-test. Qualitative observations were recorded. Results: LLM responses had significantly higher mean scores than Internet responses in the "objectivity" (3.91 ± 0.63 vs 3.36 ± 0.80, p=0.038) and "reproducibility" (3.85 ± 0.49 vs 3.00 ± 0.97, p=0.007) categories. There was no significant difference in the mean scores in "safety", "consensus", “relevance” and 'explainability". However, LLM responses lacked updated information pertaining to more contemporary concerns surrounding GLP1RA use such as the impact on fertility and mental health. Conclusions: The study highlights the importance of healthcare provider communication, as both LLM and internet searches have limitations and may perpetuate misconceptions about GLP1RAs.

JMIR Formative Res: Accuracy of Large Language Model Responses Versus Internet Searches for Common Questions About Glucagon-Like Peptide-1 Receptor Agonist Therapy: Exploratory Simulation Study #GLP1RA #ObesityTreatment #PatientEducation #DigitalHealth #LanguageModels

Wegovy 2.4 mg pens

Why Wegovy isn’t headed for OTC status—what the sources really say, why GLP-1 therapies don’t fit OTC criteria & why the conversation matters in obesity treatment.

jcst2d.com/index.php/ar...

#Wegovy #GLP1 #ObesityTreatment #DrugRegulation #MedicationSafety

Zealand Pharma logo

Zealand Pharma paused dapiglutide after early data showed no advantage over newer incretin therapies. Focus shifts to programs with stronger potential.

jcst2d.com/index.php/ne...

#ObesityTreatment #GLP1 #Incretins #MetabolicHealth

Pfizer Clinches $10 Billion Deal to Acquire Metsera, Defeating Rival Bids from Novo Nordisk Pfizer acquires Metsera in a competitive $10 billion deal, boosting its position in the obesity drug market.

Pfizer Clinches $10 Billion Deal to Acquire Metsera, Defeating Rival Bids from Novo Nordisk

#pfizer #metsera #obesitytreatment #pharmaceutical #acquisition